Premium
Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair ® )
Author(s) -
Hughes J. D. M.,
Olynyc T.,
Chapdelaine H.,
Segal L.,
Miedzybrodzki B.,
BenShoshan M.
Publication year - 2018
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.13408
Subject(s) - omalizumab , cutaneous mastocytosis , medicine , monoclonal antibody , monoclonal , dermatology , systemic mastocytosis , immunoglobulin e , antibody , immunology , mast cell
Summary Omalizumab (Xolair ® ) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.